[1] |
Xiaowei Chi, Qi Li, Yi Zhong, Tong Gong, Chuxiao Yi, Liangren Zhang, Zhenming Liu.
Discovery of potential xanthine oxidase inhibitors based on virtual screening
[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(8): 626-635.
|
[2] |
Yuxia Zhu, Lingjian Zhang, Yiming Hu, Weihua Liu, Liping Guan, Lin Lin.
Study on synthesis of naringenin derivatives and cholinesterase inhibitory activity in marine Chinese medicine
[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(8): 636-644.
|
[3] |
Chonghao Wu, Panjie Huang, Chunqi Yang, Chuan Gao, Ming Zeng.
The efficacy and safety of immune checkpoint inhibitors in malignant pleural mesothelioma: A systematic review
[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 291-301.
|
[4] |
Xiaohui Li, Qian Wang, Chennan Liu, Jiangxue Han, Sihan Liu, Tianjun Liu, Qian Wang, Yan Guan, Chunling Xiao, Xiao Wang, Yishuang Liu.
PHT427 functions as a novel inhibitor of KPC-2
[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(12): 989-997.
|
[5] |
Ying Fu, Simo Liu, Yan Ma, Nannan Wu.
Canagliflozin, an inhibitor of sodium-glucose co-transporter 2, advances in the treatment of type 2 diabetes
[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(8): 569-588.
|
[6] |
Ao Sun, Zipeng Li, Ting Liu, Xiangbao Meng, Shuchun Li, Zhongjun Li.
Improvement of Kdo's efficient large-scale chemical synthesis method
[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(2): 97-107.
|
[7] |
Huijie Lv, Tuo Xv, Jun Peng, Gang Luo, Jianqin He, Sisi Yang, Tiancheng Zhang, Shuidong Feng, Hongyan Ling.
Dihydromyricetin improves liver fat deposition in high-fat diet-induced obese mice
[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(11): 824-839.
|
[8] |
Yuehua Liu, Zhangqin Xue, Jianming Wei, Ruomeng Wei, Baodong Yin, Aiqin Liu.
Study on drug synthesis and activity of sodium olpadronate
[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(11): 883-892.
|
[9] |
Lijuan Jiang, Tingting Cao, Ruoyi Yang, Ying Li, Lin Dong, Shufan Yin.
Design, synthesis, and biological evaluation of a series of novel cordycepin derivatives
[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(1): 55-67.
|
[10] |
Qian Wang, Chennan Liu, Jiangxue Han, Sihan Liu, Chunling Xiao, Yan Guan, Xinghua Li, Ying Wang, Xiao Wang, Jianzhou Meng, Maoluo Gan, Yishuang Liu.
(–)-Epicatechin gallate serves as a novel new delhi metallo-β-lactamase-1 (NDM-1) inhibitor
[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 716-724.
|
[11] |
Shiqi Xu, Liyan Zhu, Chao Hao, Wenqian Liu, Chenglong Chen, Yongyi Chen, Aiqin Liu.
Synthesis of a novel series of amino acid prodrugs based on tegafur and evaluation of their antitumor activity
[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 743-753.
|
[12] |
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center.
Cyclic peptide molecular biosynthesis-the group of Professor Ming Ma discovered the first catalytic isomerization/cyclic bifunctional thioesterase and analyzed its crystal structure
[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 778-779.
|
[13] |
Aris Stiawan, Eti Nurwening Sholikhah, Yehezkiel Steven Kurniawan, Yoga Priastomo, Jumina.
Synthesis, cytotoxicity assay, and molecular docking study of hydroxychalcone derivatives as potential tyrosinase inhibitors
[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(8): 634-644.
|
[14] |
Chunxing Li, Yuanmin Zhu, Hua Liu, Zhao Xu.
Efficacy of prokinetic drugs in combination with proton pump inhibitors versus proton pump inhibitors alone in the treatment of gastroesophageal reflux disease: a meta-analysis
[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(4): 347-356.
|
[15] |
Shaohong Luo, Liangliang Dong, Yiyuan Li, Dan Xu, Min Chen.
Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer
[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(3): 253-263.
|